Portuguese 
Spanish 
Published Research in Cellular Signalling in 2024 Shows That Blocking the Protein AP2A1 May Reverse Cell Senescence and Open New Perspectives for Regenerative Medicine
In 2024, researchers from Osaka University in Japan announced a relevant discovery for the biology of aging.
In the study published in the scientific journal Cellular Signalling, the team identified the protein AP2A1 as a central piece in the process of cell senescence, a phase associated with the aging of human cells.
In laboratory experiments, scientists blocked the protein and observed that aged cells resumed cell division and reacquired typical characteristics of young cells.
-
She spent 73 years breathing inside an iron lung, survived the aftereffects of polio, and became the last woman in the United States dependent on the equipment before dying at 78 years old.
-
Brazilian students created a $1 filter using pine bark, cotton, and 3D-printed parts to clean cassava wastewater, reduce the toxicity of a hazardous waste, and transform contaminated water into biofertilizer.
-
Astronaut from Artemis II steps down after mission to the Moon and decision surprises after a record of 406,771 km, a historic 10-day journey, and an unprecedented achievement for Canada.
-
A fossil kept for years in a small museum in Montreal concealed 450-million-year-old soft tissue, a discovery that has only happened once before in history.
The results indicate a partial reversal of aging-related markers, although the tests are still limited to cell models.
Technical Investigation Reveals Central Role of AP2A1 in Aging
During aging, cells increase in size, lose functionality, and enter into cell senescence, a state in which they stop dividing but remain active in the organism.
According to Pirawan Chantachotikul, the author of the study, senescent cells exhibit thicker stress fibers than young cells.
These structures contribute to the increase in cell size and loss of mobility.
In the 2024 scientific article, the team reported finding higher levels of the protein AP2A1 in these aged cells.
The researchers associate this elevated concentration with cellular stiffening and maintenance of the senescent state.
Moreover, the accumulation of senescent cells in the organism is related to diseases such as osteoporosis, cardiovascular diseases, some types of cancer, and neurodegenerative disorders, as described in the study.
Blocking the Protein Reverses Characteristics of Cell Aging
In laboratory tests, scientists directly adjusted the expression of AP2A1 in different types of human cells.
When they deactivated the protein in aged cells, those cells began to divide again and reduced in size.
According to Shinji Deguchi, co-author of the research, the suppression of AP2A1 reversed senescence and stimulated cell renewal.
On the other hand, when researchers increased the amount of the protein in young cells, cellular aging accelerated.
This result reinforces the regulatory role of AP2A1 in controlling the functional age of cells.
Combination with IU1 Reduces Biological Markers of Aging
In addition to blocking the protein, the team applied the compound IU1, a substance that helps remove damaged proteins within cells.
This process acts as a type of “molecular cleaning.”
When they combined the blocking of AP2A1 with the use of IU1, scientists recorded measurable reductions in biological markers of aging.
The data indicates a partial reversal of the so-called cellular biological clock in a controlled environment.
Potential Impacts for Regenerative Medicine
Although the tests have only occurred in the laboratory, the authors highlight the potential of the discovery for regenerative medicine.
If future studies confirm safety and efficacy in more complex organisms, science may develop strategies to prevent diseases associated with aging even before the first symptoms.
Intervening directly in cellular mechanisms represents an important advance in understanding human aging.
Still, the team from Osaka University emphasizes that the research remains in its early stages.
New studies will need to confirm these results before any clinical application.
In light of this scenario, the discovery of the protein AP2A1 raises an inevitable question: Are We Facing a New Chapter in the Pursuit of Greater Human Longevity?
